Market Capitalization

The high court's 7-2 decision on Roundup not only ends a legal saga for Bayer but signals a major shift in product liability across all federally regulated industries.

French med-tech firm IMPLANET is using strategic sponsorships and key partnerships to challenge giants in the $14B spinal device market. Here's the bottom line.

In a landmark ruling, the Supreme Court has shielded Bayer from 'failure-to-warn' claims, potentially erasing billions in liability and reshaping product law.

The company once known for late-night snacks is pivoting hard, aiming to acquire a Taiwanese tech giant in a deal that could be worth over a billion dollars.

The chocolatier's dual openings signal growth, but a look at the books reveals a deeper story of strategic overhaul, franchisee faith, and a high-stakes pivot.

Vaxart’s COVID pill vaccine trial sees funding cut, yet new funds for data analysis signal a complex bet by BARDA on the future of pandemic response.

Greenland Mines charts a bold path for its Skaergaard project, but can it navigate the treacherous terrain of Arctic mining and financial instability?

RenX Enterprises pushes forward with its advanced soil facility, but a key mill is delayed, highlighting the clash between green-tech vision and reality.

The tech firm is buying back nearly half its shares. We analyze if this massive tender offer is a bold bet on its AI future or a retreat from growth.

After an 80% stock collapse, Dye & Durham replaces its CEO. A new 'Transformation Committee' now steers the ship, tasked with restoring discipline and navigating a critical strategic review.

Replenish Nutrients is partnering with Hutterite colonies to build a decentralized production network. Is this a new model for capital-light industrial growth?

Bionano Genomics brings back OGM pioneer Dr. Alex Hastie as CSO. It's a strategic move to accelerate clinical adoption and restore investor confidence.

Facing delisting, Virax Biolabs consolidates its shares in a bid to survive. This move buys time, but the real test lies in its innovative T-cell technology.

The scramble to offer SpaceX derivatives reveals the true story: the invisible financial infrastructure that now moves markets at unprecedented speed.

A new $5M partnership promises better patient support. We analyze the model, the money, and the ethical tightrope of pharma-nonprofit collaborations.

New data reveals a massive surge in stock futures trading on crypto platforms, led by a 1,000% jump in Micron. Is the AI boom redrawing the map for investors?

Vedanta Group's historic demerger splits the conglomerate into five focused firms. This bold move aims to unlock value and power India's growth.

The home-care provider just restructured over a billion in debt. While the company calls it an optimization, the data reveals a story of survival.

SCWorx gets a final chance to stay on Nasdaq, but it's pinned on a high-risk reverse stock split—a move that failed just months ago. Can it succeed?

Bitget's listing of Arcium (ARX) is more than a new token. It’s a bet on confidential computing, a technology poised to revolutionize AI and DeFi.